title: Effect of a gastro-protective agent, rebamipide, on symptom improvement in patients with functional dyspepsia: a double-blind placebo-controlled study in Japan.
abstract: OBJECTIVE
  Although mucosal protective agents have been used frequently for treatment of symptomatic gastritis, there has been no well-controlled study of functional dyspepsia. The aim of this study was to assess the efficacy of a 4-week treatment with rebamipide for the relief of overall dyspeptic symptoms and the improvement in quality of life from an untreated baseline in Japanese patients with functional dyspepsia.
  
  
  METHODS
  In a double-blinded, randomized, placebo-controlled, single-center study, 81 patients with functional dyspepsia were recruited and treated with rebamipide (100 mg, t.i.d.) or placebo for 4 weeks. Symptoms were assessed at baseline and at the end of the study period by a symptom questionnaire. Quality of life was evaluated by the QPD 32.
  
  
  RESULTS
  Data was analyzed for symptoms from 38 patients who received rebamipide and 33 patients who received placebo treatment. Overall symptoms were significantly improved in both the rebamipide and placebo treatment groups from the untreated baseline after 4 weeks of treatment, and the mean changes in overall symptoms were not significantly different between the groups. However, the improvement in symptom score was significantly greater in the treatment arm than in the placebo arm for three items, which were bloating, belching, and pain or discomfort that was relieved after a meal. Regarding quality of life, social restriction and pain intensity were significantly improved in the rebamipide treatment group in per-protocol analysis (P = 0.048 and P = 0.031, respectively).
  
  
  CONCLUSIONS
  Although rebamipide was not significantly better than placebo in reducing overall symptoms by 4 weeks' treatment, it may partially improve the symptoms. It may also be beneficial in improvement of quality of life in Japanese patients with functional dyspepsia.
authors.affiliation: Department of Gastroenterology, Hyogo College of Medicine, Hyogo, Japan. miwahgi@hyo-med.ac.jp
authors.forename: Hiroto
authors.initials: H
authors.lastname: Miwa
authors.forename: Taro
authors.initials: T
authors.lastname: Osada
authors.forename: Akihito
authors.initials: A
authors.lastname: Nagahara
authors.forename: Toshifumi
authors.initials: T
authors.lastname: Ohkusa
authors.forename: Mariko
authors.initials: M
authors.lastname: Hojo
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Tomita
authors.forename: Kazutoshi
authors.initials: K
authors.lastname: Hori
authors.forename: Takayuki
authors.initials: T
authors.lastname: Matsumoto
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Sato
mesh_terms: D000328:Adult; D000368:Aged; D000409:Alanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D004311:Double-Blind Method; D004415:Dyspepsia / Q000188:drug therapy* / Q000523:psychology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007564:Japan; D008297:Male; D008875:Middle Aged; D010147:Pain Measurement; D011788:Quality of Life; D015363:Quinolones / Q000627:therapeutic use*; D012189:Retrospective Studies; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
chemical_list: D000897:Anti-Ulcer Agents; D015363:Quinolones; C052785:rebamipide; D000409:Alanine